Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Pharmacovigilance Market Research Report Information By Clinical Trial Phase (Phase IV, Phase III, Phase II, Phase I, Pre-clinical), By Service Provider (In-house, Contract Outsourcing), By Type (Spontaneous Reporting, Cohort Event Monitoring, Intensified ADR Reporting, EHR Mining) and By End-User (Hospitals, Research Organizations, Pharmaceutical Companies)- Forecast to 2032


ID: MRFR/HC/6979-HCR | 111 Pages | Author: Kinjoll Dey| April 2024

Research Methodology on Pharmacovigilance Market


Introduction


Pharmacovigilance (PV) is a crucial activity that concerns the safety of medicines, monitoring their safety profile, and detecting and mitigating risks associated with their use. This research report is aimed at studying the current market trends and future developments in the pharmacovigilance market. The report provides an in-depth analysis of market opportunities, competitive dynamics and restraining factors associated with the market.


Research Methodology


The research implemented for this report is based on a quantitative approach and data collected through a combination of primary and secondary research methods. The primary research for the report is conducted using interviews with key opinion leaders & industry experts. The research methodology used to gather the necessary data includes but is not limited to:


Primary research:


Primary research is conducted to obtain relevant data pertaining to the pharmacovigilance market. In-depth interviews are conducted with industry experts and key opinion leaders as part of the primary research. Primary research also includes collecting information through surveys conducted among selected participants in the industry.


Secondary research:


Secondary research is conducted to obtain additional data sources to complement the primary research. The sources of secondary data collected include both on and offline sources. The sources of secondary data include but are not limited to trade journals and reports published by industry associations, government sources (national and international), newspapers and magazines, academic institutions and industry reports.


Data Analysis


Data collected through primary and secondary research is carefully analyzed using a combination of qualitative and quantitative analysis to obtain data which could best describe the market dynamics. Statistical tools such as descriptive analyses, regressions, SWOT analysis and PESTEL analysis are all used for data analysis and the results are used to gain an in-depth understanding of the market.


Data Validation


Data collected and analyzed is verified through further secondary sources to ensure the accuracy, reliability and credibility of data used in the report. The data is also triangulated and benchmarked against current and future market trends to ensure accuracy and reliability.


Scope of the Study


The scope of this study is to analyze the current market trends and future development in the pharmacovigilance market. This includes providing an in-depth analysis of market opportunities in North America, Europe, Asia-Pacific, and the Rest of the World (RoW). The report also provides an analysis of market drivers, restraints, and competitive dynamics associated with the pharmacovigilance market.


Conclusion


Through the implementation of this comprehensive research methodology, the current and future trends in the pharmacovigilance market are analyzed. The study includes a detailed analysis of the market segments, opportunities and competitive dynamics among the market players. The report also provides an in-depth analysis of the drivers, restraints, and future market prospects related to the pharmacovigilance market. The data collected is verified through triangulation and benchmarking against current and future market trends, thereby ensuring accuracy and reliability.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Please fill in Business Email for Quick Response

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

6. GLOBAL PHARMACOVIGILANCE MARKET, BY CLINICAL TRIAL PHASE

6.1. Overview

6.2. Pre-Clinical

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3. Phase I

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4. Phase II

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.5. Phase III

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.6. Phase IV

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7. GLOBAL PHARMACOVIGILANCE MARKET, BY SERVICE PROVIDER

7.1. Overview

7.2. In-House

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3. Contract Outsourcing

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8. GLOBAL PHARMACOVIGILANCE MARKET, BY TYPE

8.1. Overview

8.2. Spontaneous Reporting

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3. Intensified ADR Reporting

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.4. Targeted Spontaneous Reporting

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.5. Cohort Event Monitoring

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.6. EHR Mining

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9. GLOBAL PHARMACOVIGILANCE MARKET, BY END USER

9.1. Overview

9.2. Hospitals

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.3. Research Organizations

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.4. Pharmaceutical Companies

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.5. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

10. GLOBAL PHARMACOVIGILANCE MARKET, BY REGION

10.1. Overview

10.2. Americas

10.2.1. North America

10.2.1.1. US

10.2.1.2. Canada

10.2.2. Latin America

10.3. Europe

10.3.1. Western Europe

10.3.1.1. Germany

10.3.1.2. France

10.3.1.3. Italy

10.3.1.4. Spain

10.3.1.5. UK

10.3.1.6. Rest of Western Europe

10.3.2. Eastern Europe

10.4. Asia-Pacific

10.4.1. Japan

10.4.2. China

10.4.3. India

10.4.4. Australia

10.4.5. South Korea

10.4.6. Rest of Asia-Pacific

10.5. Middle East & Africa

10.5.1. Middle East

10.5.2. Africa

11. COMPANY LANDSCAPE

11.1.1. Overview

11.1.2. Competitive Analysis

12. COMPANY PROFILES

12.1. Accenture

12.1.1. Company Overview

12.1.2. Product Type Overview

12.1.3. Financial Overview

12.1.4. Key Developments

12.1.5. SWOT Analysis

12.1.6. Key Strategies

12.2. ArisGlobal

12.2.1. Company Overview

12.2.2. Product Type Overview

12.2.3. Financial Overview

12.2.4. Key Developments

12.2.5. SWOT Analysis

12.2.6. Key Strategies

12.3. BioClinica

12.3.1. Company Overview

12.3.2. Product Type Overview

12.3.3. Financial Overview

12.3.4. Key Developments

12.3.5. SWOT Analysis

12.3.6. Key Strategies

12.4. Capgemini

12.4.1. Company Overview

12.4.2. Product Type Overview

12.4.3. Financial Overview

12.4.4. Key Developments

12.4.5. SWOT Analysis

12.4.6. Key Strategies

12.5. Clinquest Group BV

12.5.1. Company Overview

12.5.2. Product Type Overview

12.5.3. Financial Overview

12.5.4. Key Developments

12.5.5. SWOT Analysis

12.5.6. Key Strategies

12.6. Cognizant

12.6.1. Company Overview

12.6.2. Product Type Overview

12.6.3. Financial Overview

12.6.4. Key Developments

12.6.5. SWOT Analysis

12.6.6. Key Strategies

12.7. Foresight Group International AG

12.7.1. Company Overview

12.7.2. Product Type Overview

12.7.3. Financial Overview

12.7.4. Key Developments

12.7.5. SWOT Analysis

12.7.6. Key Strategies

12.8. IBM Corporation

12.8.1. Company Overview

12.8.2. Product Type Overview

12.8.3. Financial Overview

12.8.4. Key Developments

12.8.5. SWOT Analysis

12.8.6. Key Strategies

12.9. ICON PLC

12.9.1. Company Overview

12.9.2. Product Type Overview

12.9.3. Financial Overview

12.9.4. Key Developments

12.9.5. SWOT Analysis

12.9.6. Key Strategies

12.10. IMEDGlobal

12.10.1. Company Overview

12.10.2. Product Type Overview

12.10.3. Financial Overview

12.10.4. Key Developments

12.10.5. SWOT Analysis

12.10.6. Key Strategies

12.11. ITClinical

12.11.1. Company Overview

12.11.2. Product Type Overview

12.11.3. Financial Overview

12.11.4. Key Developments

12.11.5. SWOT Analysis

12.11.6. Key Strategies

12.12. Laboratory Corporation of America Holdings

12.12.1. Company Overview

12.12.2. Product Type Overview

12.12.3. Financial Overview

12.12.4. Key Developments

12.12.5. SWOT Analysis

12.12.6. Key Strategies

12.13. PAREXEL International Corporation

12.13.1. Company Overview

12.13.2. Product Type Overview

12.13.3. Financial Overview

12.13.4. Key Developments

12.13.5. SWOT Analysis

12.13.6. Key Strategies

12.14. TAKE Solutions Ltd

12.14.1. Company Overview

12.14.2. Product Type Overview

12.14.3. Financial Overview

12.14.4. Key Developments

12.14.5. SWOT Analysis

12.14.6. Key Strategies

12.15. United BioSource Corporation

12.15.1. Company Overview

12.15.2. Product Type Overview

12.15.3. Financial Overview

12.15.4. Key Developments

12.15.5. SWOT Analysis

12.15.6. Key Strategies

12.16. Wipro Ltd

12.16.1. Company Overview

12.16.2. Product Type Overview

12.16.3. Financial Overview

12.16.4. Key Developments

12.16.5. SWOT Analysis

12.16.6. Key Strategies

12.17. Others

13. APPENDIX

13.1. References

13.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL PHARMACOVIGILANCE MARKET SYNOPSIS, 2020-2027

TABLE 2 GLOBAL PHARMACOVIGILANCE MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)

TABLE 3 GLOBAL PHARMACOVIGILANCE MARKET, BY CLINICAL TRIAL PHASE, 2020-2027 (USD MILLION)

TABLE 4 GLOBAL PHARMACOVIGILANCE MARKET, BY SERVICE PROVIDER, 2020-2027 (USD MILLION)

TABLE 5 GLOBAL PHARMACOVIGILANCE MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 6 GLOBAL PHARMACOVIGILANCE MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 7 GLOBAL PHARMACOVIGILANCE MARKET, BY REGION, 2020-2027 (USD MILLION)

TABLE 8 NORTH AMERICA: PHARMACOVIGILANCE MARKET, BY CLINICAL TRIAL PHASE, 2020-2027 (USD MILLION)

TABLE 9 NORTH AMERICA: PHARMACOVIGILANCE MARKET, BY SERVICE PROVIDER, 2020-2027 (USD MILLION)

TABLE 10 NORTH AMERICA: PHARMACOVIGILANCE MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 11 NORTH AMERICA: PHARMACOVIGILANCE MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 12 US: PHARMACOVIGILANCE MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 13 US: PHARMACOVIGILANCE MARKET, BY SERVICE PROVIDER, 2020-2027 (USD MILLION)

TABLE 14 US: PHARMACOVIGILANCE MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 15 US: PHARMACOVIGILANCE MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 16 CANADA: PHARMACOVIGILANCE MARKET, BY CLINICAL TRIAL PHASE, 2020-2027 (USD MILLION)

TABLE 17 CANADA: PHARMACOVIGILANCE MARKET, BY SERVICE PROVIDER, 2020-2027 (USD MILLION)

TABLE 18 CANADA: PHARMACOVIGILANCE MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 19 CANADA: PHARMACOVIGILANCE MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 20 LATIN AMERICA: PHARMACOVIGILANCE MARKET, BY CLINICAL TRIAL PHASE, 2020-2027 (USD MILLION)

TABLE 21 LATIN AMERICA: PHARMACOVIGILANCE MARKET, BY SERVICE PROVIDER, 2020-2027 (USD MILLION)

TABLE 22 LATIN AMERICA: PHARMACOVIGILANCE MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 23 LATIN AMERICA: PHARMACOVIGILANCE MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 24 EUROPE: PHARMACOVIGILANCE MARKET, BY CLINICAL TRIAL PHASE, 2020-2027 (USD MILLION)

TABLE 25 EUROPE: PHARMACOVIGILANCE MARKET, BY SERVICE PROVIDER, 2020-2027 (USD MILLION)

TABLE 26 EUROPE: PHARMACOVIGILANCE MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 27 EUROPE: PHARMACOVIGILANCE MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 28 WESTERN EUROPE: PHARMACOVIGILANCE MARKET, BY CLINICAL TRIAL PHASE, 2020-2027 (USD MILLION)

TABLE 29 WESTERN EUROPE: PHARMACOVIGILANCE MARKET, BY SERVICE PROVIDER, 2020-2027 (USD MILLION)

TABLE 30 WESTERN EUROPE: PHARMACOVIGILANCE MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 31 WESTERN EUROPE: PHARMACOVIGILANCE MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 32 EASTERN EUROPE: PHARMACOVIGILANCE MARKET, BY CLINICAL TRIAL PHASE, 2020-2027 (USD MILLION)

TABLE 33 EASTERN EUROPE: PHARMACOVIGILANCE MARKET, BY SERVICE PROVIDER, 2020-2027 (USD MILLION)

TABLE 34 EASTERN EUROPE: PHARMACOVIGILANCE MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 35 EASTERN EUROPE: PHARMACOVIGILANCE MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 36 ASIA-PACIFIC: PHARMACOVIGILANCE MARKET, BY CLINICAL TRIAL PHASE, 2020-2027 (USD MILLION)

TABLE 37 ASIA-PACIFIC: PHARMACOVIGILANCE MARKET, BY SERVICE PROVIDER, 2020-2027 (USD MILLION)

TABLE 38 ASIA-PACIFIC: PHARMACOVIGILANCE MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 39 ASIA-PACIFIC: PHARMACOVIGILANCE MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 40 MIDDLE EAST & AFRICA: PHARMACOVIGILANCE MARKET, BY CLINICAL TRIAL PHASE, 2020-2027 (USD MILLION)

TABLE 41 MIDDLE EAST & AFRICA: PHARMACOVIGILANCE MARKET, BY SERVICE PROVIDER, 2020-2027 (USD MILLION)

TABLE 42 MIDDLE EAST & AFRICA: PHARMACOVIGILANCE MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 43 MIDDLE EAST & AFRICA: PHARMACOVIGILANCE MARKET, BY END USER, 2020-2027 (USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL PHARMACOVIGILANCE MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL PHARMACOVIGILANCE MARKET

FIGURE 4 GLOBAL PHARMACOVIGILANCE MARKET SHARE, BY CLINICAL TRIAL PHASE, 2020 (%)

FIGURE 5 GLOBAL PHARMACOVIGILANCE MARKET SHARE, BY SERVICE PROVIDER, 2020 (%)

FIGURE 6 GLOBAL PHARMACOVIGILANCE MARKET SHARE, BY TYPE, 2020 (%)

FIGURE 7 GLOBAL PHARMACOVIGILANCE MARKET SHARE, BY END USER, 2020 (%)

FIGURE 8 GLOBAL PHARMACOVIGILANCE MARKET SHARE, BY REGION, 2020 (%)

FIGURE 7 AMERICAS: PHARMACOVIGILANCE MARKET SHARE BY REGION, 2020 (%)

FIGURE 9 NORTH AMERICA: PHARMACOVIGILANCE MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 10 EUROPE: PHARMACOVIGILANCE MARKET SHARE, BY REGION, 2020 (%)

FIGURE 11 WESTERN EUROPE: PHARMACOVIGILANCE MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 12 ASIA-PACIFIC: PHARMACOVIGILANCE MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 13 MIDDLE EAST & AFRICA: PHARMACOVIGILANCE MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 14 GLOBAL PHARMACOVIGILANCE MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 15 ACCENTURE.: KEY FINANCIALS

FIGURE 16 ACCENTURE: SEGMENTAL REVENUE

FIGURE 17 ACCENTURE: REGIONAL REVENUE

FIGURE 18 ARISGLOBAL: KEY FINANCIALS

FIGURE 19 ARISGLOBAL: SEGMENTAL REVENUE

FIGURE 20 ARISGLOBAL: REGIONAL REVENUE

FIGURE 21 BIOCLINICA: KEY FINANCIALS

FIGURE 22 BIOCLINICA: SEGMENTAL REVENUE

FIGURE 23 BIOCLINICA: REGIONAL REVENUE

FIGURE 24 CAPGEMINI: KEY FINANCIALS

FIGURE 25 CAPGEMINI: SEGMENTAL REVENUE

FIGURE 26 CAPGEMINI: REGIONAL REVENUE

FIGURE 27 CLINQUEST GROUP B.V.: KEY FINANCIALS

FIGURE 28 CLINQUEST GROUP B.V.: SEGMENTAL REVENUE

FIGURE 29 CLINQUEST GROUP B.V.: REGIONAL REVENUE

FIGURE 30 COGNIZANT: KEY FINANCIALS

FIGURE 31 COGNIZANT: SEGMENTAL REVENUE

FIGURE 32 COGNIZANT: REGIONAL REVENUE

FIGURE 33 FORESIGHT GROUP INTERNATIONAL AG: KEY FINANCIALS

FIGURE 34 FORESIGHT GROUP INTERNATIONAL AG: SEGMENTAL REVENUE

FIGURE 35 FORESIGHT GROUP INTERNATIONAL AG: REGIONAL REVENUE

FIGURE 36 IBM CORPORATION: KEY FINANCIALS

FIGURE 37 IBM CORPORATION: SEGMENTAL REVENUE

FIGURE 38 IBM CORPORATION: REGIONAL REVENUE

FIGURE 39 ICON PLC: KEY FINANCIALS

FIGURE 40 ICON PLC: SEGMENTAL REVENUE

FIGURE 41 ICON PLC: REGIONAL REVENUE

FIGURE 42 IMEDGLOBAL: KEY FINANCIALS

FIGURE 43 IMEDGLOBAL: SEGMENTAL REVENUE

FIGURE 44 IMEDGLOBAL: REGIONAL REVENUE

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.